 Zenggang Pan
Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2018 | 112 | 1.090 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 2 | 2024 | 19 | 1.050 |
Why?
| | Gene Rearrangement | 2 | 2024 | 148 | 0.970 |
Why?
| | Mast-Cell Sarcoma | 1 | 2024 | 6 | 0.950 |
Why?
| | Mastocytosis, Systemic | 1 | 2024 | 8 | 0.940 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2024 | 68 | 0.910 |
Why?
| | Biomarkers, Tumor | 5 | 2018 | 1181 | 0.880 |
Why?
| | Nuclear Proteins | 2 | 2024 | 663 | 0.750 |
Why?
| | Multiple Myeloma | 2 | 2025 | 125 | 0.720 |
Why?
| | Lymphoma, B-Cell | 2 | 2018 | 105 | 0.660 |
Why?
| | Plasmablastic Lymphoma | 1 | 2018 | 7 | 0.580 |
Why?
| | Erdheim-Chester Disease | 1 | 2017 | 5 | 0.580 |
Why?
| | CD3 Complex | 1 | 2018 | 103 | 0.570 |
Why?
| | Organic Cation Transport Proteins | 1 | 2016 | 30 | 0.520 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2017 | 231 | 0.490 |
Why?
| | Histiocytic Sarcoma | 1 | 2015 | 3 | 0.490 |
Why?
| | Cell Transdifferentiation | 1 | 2015 | 31 | 0.480 |
Why?
| | Lymphoma, Follicular | 1 | 2015 | 38 | 0.470 |
Why?
| | Merkel cell polyomavirus | 1 | 2014 | 4 | 0.440 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2014 | 13 | 0.440 |
Why?
| | Carcinoma, Merkel Cell | 1 | 2014 | 18 | 0.440 |
Why?
| | Polyomavirus Infections | 1 | 2014 | 28 | 0.430 |
Why?
| | Trans-Activators | 1 | 2016 | 387 | 0.430 |
Why?
| | Tumor Virus Infections | 1 | 2014 | 46 | 0.430 |
Why?
| | Lymphoma | 1 | 2014 | 195 | 0.400 |
Why?
| | B-Lymphocytes | 3 | 2018 | 815 | 0.280 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 315 | 0.230 |
Why?
| | Immunoglobulin Light Chains | 1 | 2025 | 40 | 0.230 |
Why?
| | Osteolysis | 1 | 2025 | 18 | 0.230 |
Why?
| | Aged, 80 and over | 3 | 2024 | 7061 | 0.220 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1424 | 0.210 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2024 | 201 | 0.200 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 1036 | 0.200 |
Why?
| | Lymph Nodes | 2 | 2015 | 469 | 0.190 |
Why?
| | Male | 11 | 2025 | 63491 | 0.190 |
Why?
| | Herpesvirus 4, Human | 2 | 2018 | 152 | 0.170 |
Why?
| | Fatal Outcome | 2 | 2017 | 300 | 0.170 |
Why?
| | Humans | 16 | 2025 | 129212 | 0.160 |
Why?
| | Histocytochemistry | 2 | 2018 | 83 | 0.160 |
Why?
| | Middle Aged | 6 | 2018 | 31075 | 0.160 |
Why?
| | Aged | 5 | 2018 | 22030 | 0.150 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 7 | 0.150 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 2017 | 5 | 0.150 |
Why?
| | Chylothorax | 1 | 2017 | 16 | 0.140 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2018 | 93 | 0.140 |
Why?
| | Cell Cycle Checkpoints | 1 | 2017 | 95 | 0.140 |
Why?
| | Female | 7 | 2024 | 68600 | 0.140 |
Why?
| | Pleural Effusion | 1 | 2017 | 51 | 0.140 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 8 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2018 | 213 | 0.130 |
Why?
| | Organic Cation Transporter 2 | 1 | 2016 | 8 | 0.130 |
Why?
| | Genetic Association Studies | 1 | 2018 | 360 | 0.130 |
Why?
| | DNA, Viral | 2 | 2016 | 349 | 0.120 |
Why?
| | S100 Proteins | 1 | 2015 | 36 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 278 | 0.120 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 60 | 0.120 |
Why?
| | Biopsy, Fine-Needle | 1 | 2015 | 66 | 0.120 |
Why?
| | Cell Lineage | 1 | 2016 | 333 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 857 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 432 | 0.110 |
Why?
| | Antigens, Viral, Tumor | 1 | 2014 | 7 | 0.110 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 2014 | 12 | 0.110 |
Why?
| | PAX5 Transcription Factor | 1 | 2014 | 14 | 0.110 |
Why?
| | Cell Cycle Proteins | 1 | 2017 | 586 | 0.110 |
Why?
| | Mutation | 1 | 2024 | 3715 | 0.110 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1696 | 0.110 |
Why?
| | Receptors, Cell Surface | 1 | 2015 | 378 | 0.100 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 318 | 0.100 |
Why?
| | Immunophenotyping | 1 | 2014 | 311 | 0.100 |
Why?
| | Antigens, CD | 1 | 2015 | 488 | 0.100 |
Why?
| | Antineoplastic Agents | 3 | 2018 | 2058 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1565 | 0.100 |
Why?
| | Sex Factors | 1 | 2018 | 1961 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1834 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1364 | 0.090 |
Why?
| | Young Adult | 2 | 2018 | 12396 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1928 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2281 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2017 | 1170 | 0.070 |
Why?
| | Adolescent | 2 | 2018 | 20371 | 0.070 |
Why?
| | Adult | 3 | 2018 | 35464 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2014 | 823 | 0.060 |
Why?
| | Doxorubicin | 2 | 2017 | 325 | 0.060 |
Why?
| | Prognosis | 2 | 2025 | 3791 | 0.050 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 428 | 0.050 |
Why?
| | Lung | 1 | 2015 | 3916 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 276 | 0.050 |
Why?
| | Viral Tropism | 1 | 2018 | 29 | 0.040 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2025 | 1354 | 0.040 |
Why?
| | Karyotyping | 1 | 2018 | 107 | 0.040 |
Why?
| | Virus Activation | 1 | 2018 | 87 | 0.040 |
Why?
| | Virus Latency | 1 | 2018 | 83 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2018 | 150 | 0.040 |
Why?
| | Cytarabine | 1 | 2017 | 57 | 0.040 |
Why?
| | Prednisolone | 1 | 2017 | 82 | 0.030 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2017 | 43 | 0.030 |
Why?
| | Etoposide | 1 | 2017 | 148 | 0.030 |
Why?
| | Asparaginase | 1 | 2016 | 29 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 369 | 0.030 |
Why?
| | Vincristine | 1 | 2017 | 109 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2017 | 229 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 328 | 0.030 |
Why?
| | Europe | 1 | 2016 | 362 | 0.030 |
Why?
| | North America | 1 | 2016 | 290 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1243 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 384 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1087 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1156 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 10189 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2856 | 0.020 |
Why?
| | Mice | 2 | 2018 | 16861 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4072 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2736 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2501 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4049 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2525 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3390 | 0.020 |
Why?
| | Animals | 2 | 2018 | 35219 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3968 | 0.020 |
Why?
| | Infant | 1 | 2018 | 9016 | 0.010 |
Why?
|
|
Pan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|